Oct 01, 2021 · This is the American ICD-10-CM version of Z79.811 - other international versions of ICD-10 Z79.811 may differ. Applicable To Long term (current) use of anastrozole (Arimidex) Long term (current) use of exemestane (Aromasin) Long term (current) use of letrozole (Femara) The following code (s) above Z79.811 contain annotation back-references
Apr 16, 2018 · If the patient is currently taking one of the drugs listed above, then the code at Z79.811, Long-term use (current) aromatase inhibitors should be assigned. References: ICD-10-CM Alphabetic and Tabular Index cancer.gov/publications/dictionaries/cancer-terms/def/aromatase-inhibitor ncbi.nlm.nih.gov/pmc/articles/PMC2228389/
Oct 01, 2021 · Z79.84 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z79.84 became effective on October 1, 2021. This is the American ICD-10-CM version of Z79.84 - other international versions of ICD-10 Z79.84 may differ. Applicable To
ICD-10-CM Code for Long term (current) use of aromatase inhibitors Z79.811 ICD-10 code Z79.811 for Long term (current) use of aromatase inhibitors is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Z79.811Long term (current) use of aromatase inhibitors Z79. 811 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z79. 811 became effective on October 1, 2021.
ICD-10 Code ICD-10 Description Assign when immunodeficiency is due to: D84. 821 Immunodeficiency due to drugs Medications that interfere with the immune system. These medications include immunosuppressants, corticosteroids, and chemotherapy.
Aromatase inhibitors (AIs) lower estrogen levels by stopping an enzyme in fat tissue (called aromatase) from changing other hormones into estrogen. (Estrogen can fuel the growth of breast cancer cells.) These drugs don't stop the ovaries from making estrogen.Dec 16, 2021
89 as the primary diagnosis and the specific drug dependence diagnosis as the secondary diagnosis. For the monitoring of patients on methadone maintenance and chronic pain patients with opioid dependence use diagnosis code Z79. 891, suspected of abusing other illicit drugs, use diagnosis code Z79. 899.
Systemic lupus erythematosus, unspecified M32. 9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Z92. 25 - Personal history of immunosuppression therapy. ICD-10-CM.
ARIMIDEX is a potent and selective aromatase inhibitor undergoing evaluation as a treatment for postmenopausal women with advanced breast cancer. Studies examining the pharmacology of ARIMIDEX were conducted in both animals and humans.
Aromatase InhibitorsAnastrozole (Arimidex)Exemestane (Aromasin)Letrozole (Femara)
There are three aromatase inhibitors: anastrozole, exemestane, and letrozole.
ICD-10 code Z79. 899 for Other long term (current) drug therapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
899 Other long term (current) drug therapy.
Z79. 83 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Z79.811 is a valid billable ICD-10 diagnosis code for Long term (current) use of aromatase inhibitors . It is found in the 2021 version of the ICD-10 Clinical Modification (CM) and can be used in all HIPAA-covered transactions from Oct 01, 2020 - Sep 30, 2021 .
Z79.811 also applies to the following: Inclusion term (s): Long term (current) use of anastrozole (Arimidex) Long term (current) use of exemestane (Aromasin) Long term (current) use of letrozole (Femara) MS-DRG - Medicare Severity-Diagnosis Related Group.
DO NOT include the decimal point when electronically filing claims as it may be rejected. Some clearinghouses may remove it for you but to avoid having a rejected claim due to an invalid ICD-10 code, do not include the decimal point when submitting claims electronically. See also:
Z79.811 is a billable diagnosis code used to specify a medical diagnosis of long term (current) use of aromatase inhibitors. The code Z79.811 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.
Additional terms found only in the Alphabetic Index may also be assigned to a code. Long term (current) use of anastrozole (Arimidex) Long term (current) use of exemestane (Aromasin) Long term (current) use of letrozole (Femara)
Z79.811 is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.